TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With (Serious) Adverse Event Related to the Medical Device
Endpoint domain: Adverse events/effects
Primary endpoint: Monocyte phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of ulcer surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women agreeing to randomisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean change in gadolinium enhanced lesion magnetization transfer ratio (MTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Delta MTR lesion MTR differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CAPS Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 18F-EF5 standardized uptake values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor to normal tissue (T:N) ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Operative Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in SF-36 scale results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hemoglobin A1c (A1c) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective response detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of dapivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal fluid levels of dapivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal tissue levels of dapivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective adherence to ICS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants With Successful Response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma oxalate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total and free testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak Propulsive Ground Reaction Force on the Prosthetic Side During Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Perceived Comfort When Using Different Prosthetic Feet During Walking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Propulsive Ground Reaction Force on the Prosthetic Side During Running
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Perceived Comfort When Using Different Prosthetic Feet During Running
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cancellous Bone Formation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effects of placental transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in splanchnic regional tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton 17 item scale score for depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change of Bone Mineral Density in Lumbar and Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Montgomery-Åsberg rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Head motion during MRI scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes of the per-oral endoscopic myotomy (POEM) procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Extended Short Physical Performance Battery (eSPPB)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardioventilatory coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 42-day adequate clinical and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal anti-tumor immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first post-operative pain medication consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant-related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: changes of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Length of Penile Prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air trapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Treatment Success at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Yield of the Sample Obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Verbal learning and memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Verbal Fluency Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Functioning Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of severity of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological quality of samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Field of view of GlasScope surgical microscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Depth of field of GlasScope surgical microscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 3D perception of GlasScope surgical microscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Breathing Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: additional unplanned major surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Scale (CGIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to reach plasma peak concentration [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The area under the concentration-time curve from zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in antiH1N1 or antiH3N2 or anti-B haemagglutination inhibition antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Plasmodium Falciparum Parasitemia
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Isokinetic Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fatiguability
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Appropriateness of the treatment received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Energy intake (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality after severe traumatic brain injury
Endpoint domain: Mortality/survival
Primary endpoint: Area Under Effect Curve (AUEC) for Neopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Change From Baseline for Neopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of Volatile Organic Compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: anti-Xa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: suPAR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Appetite as Measured by a Visual Analogue Scale From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection-Related Hospital Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Signal-to-noise ratio of glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smoking Rate (# cigarettes per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute change in lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional L-DOPA therapy or dose increase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of reported deterioration using the PSP rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage change in serum LDL-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent in normal glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of discomfort during barostat
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence and intensity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores following painful stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep epithelial disruption, other genital symptoms, or other systemic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: HIV infection as measured by seroconversion
Endpoint domain: Mortality/survival
Primary endpoint: percentage of missed follow up data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: plasma levels of BAs and SCFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Latencies of intracranial responses to own-name uttered by neutral voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Latencies of intracranial responses to own-name uttered by expressive voices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spinal Block Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of Liver Hydroxysteroid 17β Dehydrogenase 13 (HSD17B13) mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) and Treatment-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: absolute blood lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: absolute blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference of scores rating by Aronchick Preparation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ear complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with recurrent stroke
Endpoint domain: Mortality/survival
Primary endpoint: peripheral fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pressure pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative referred pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to the prescribed IWT-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: COVID-19 infection rate among health care workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean reductions in probing pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth Weight Per Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable hookworm infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in DCE-MRI and DCE-CT vascular parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristic differences in EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes of plasma ox-LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of anemia status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: responsiveness to EPO therapy and severity of atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of pressure injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fertilization Proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Femoral dynamic arterial compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Plasma Concentration (CMAX) of drug terbinafine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of drug terbinafine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucosinolate Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with underinflation or overinflation of cuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Showed no Significant Irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in cue-induced brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mortality (all)
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalization > 14 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Long-term-illness (with > 30 days off work)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cytokine variability of IL-6, IL-8, IL-10, and TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Two point discrimination test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child Anxiety Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Area of Treatment Sites Requiring Autografting by Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Classified as a Responder (Based on Durable Wound Closure at Month 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Global Esthetic Improvement Scale (GEIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wearing Compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of overall severe complications following the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of completeness of neoplastic tissue resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local recurrence of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Duration of Sensory Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment of the Lower Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Musculoskeletal Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distance between tibial tuberosity and trochlear sulcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic symptom score (COMPASS 31)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Utilization of Services (30 Days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Utilization of Services (60 Days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Utilization of Services (180 Days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Utilization of Services (365 Days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Biochemical Response Rate (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major congenital malformation
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum morphine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Tachyphylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IRB approvals of the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with proteomic data received at the Operations and Biostatistics Center
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of differentially expressed biomarker proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival at 12-weeks
Endpoint domain: Mortality/survival
Primary endpoint: PK parameters of FTD, FTY, and TPI in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Injection-site Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: immune response to vaccine specific HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Adverse Events Within 1 Year Related to AST-OPC1 Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Generalized anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in C-Peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood liquid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Levels of fecal elastase-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in weekly time in sedentary activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in elbow pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologist Confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Activity adherence rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Normalization of cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity of tic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: longevity of ceramic crowns
Endpoint domain: Mortality/survival
Primary endpoint: OA pain intensity in target hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total AUSCAN score in target hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global rating of disease activity by patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status